Alaunos Therapeutics to Report First Quarter 2022 Financial Results on May 16, 2022
Alaunos Therapeutics (TCRT) is set to announce its financial results for the first quarter ending March 31, 2022, on May 16, 2022, before U.S. market opening.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Alaunos Therapeutics (TCRT) is set to announce its financial results for the first quarter ending March 31, 2022, on May 16, 2022, before U.S. market opening. A conference call will follow at 8:30 a.m. ET to discuss the results and provide a corporate update. Interested parties can join via phone or live webcast, with the event archived for 30 days post-call. Alaunos focuses on developing T-cell receptor therapies using proprietary gene transfer technology, with collaborations with MD Anderson Cancer Center and the National Cancer Institute.
Details
News Market Reaction – TCRT
The recorded move for TCRT in the trading session of this news was -1.45%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HOUSTON, May 09, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced that it will report financial results for the first quarter ended March 31, 2022 on Monday, May 16, 2022, before the open of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:30 a.m. ET to provide a corporate update and review the financial results.
The conference call can be accessed by dialing 844-309-0618 (United States) or 661-378-9465 (International) with the conference code 2495623. A live webcast may be accessed using the link here, or by visiting the “Investors” section of the Alaunos website at www.alaunos.com. After the live webcast, the event will be archived on the Company’s website for approximately 30 days after the call.
About Alaunos Therapeutics
Alaunos is a clinical-stage oncology-focused cell therapy company, focused on developing T-cell receptor (TCR) therapies based on its proprietary, non-viral Sleeping Beauty gene transfer technology and its TCR library targeting shared tumor-specific hotspot mutations in key oncogenic genes including KRAS, TP53 and EGFR. The Company has clinical and strategic collaborations with The University of Texas MD Anderson Cancer Center and the National Cancer Institute. For more information, please visit www.alaunos.com.
Investor Relations Contact:
Alex Lobo
Stern Investor Relations
Alex.lobo@sternir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.